Abstract
We aimed to evaluate the association between plasma epidermal growth factor (EGF) and the availability of dopamine transporter (DAT) measured from 123I-FP-CIT single-photon emission computed tomography in healthy controls in this study. Volume of interest template was applied to measure specific binding ratios (SBRs) of caudate nucleus, putamen, and striatum representing DAT availability as follows; SBR = (target– cerebellum)/cerebellum. Plasma EGF was negatively correlated with the availabilities of both caudate nucleus (r = −0.261, p = 0.019), and putamen (r = −0.341, p = 0.002). After dividing subjects according to Apo E genotyping, DAT availability of caudate nucleus of Apo e4 non-carriers (n = 60) showed the positive correlation with cerebrospinal fluid (CSF) α-synuclein (r = 0.264, p = 0.042). Plasma EGF was negatively correlated with DAT availabilities of Apo e4 non-carriers. Further studies are needed to clarify underlying mechanisms of this phenomenon.
Highlights
PD is a clinical syndrome showing bradykinesia, tremor, rigidity, and postural instability
dopamine transporter (DAT) availabilities in caudate nucleus (r = −0.313, p = 0.004) showed a reduction with aging as expected
When subjects were divided according to Apo e4 genotyping, Aβ1–42 was higher in Apo e4 non-carriers than Apo e4 carriers
Summary
PD is a clinical syndrome showing bradykinesia, tremor, rigidity, and postural instability. It is characterized by the loss of dopaminergic neuron of the substantia nigra, and the presence of intraneuronal cytoplasmic inclusion[6,7]. As 123I-FP-CIT reflects the striatal DAT density[8], the availability of DAT measured from 123I-FP-CIT single-photon emission computed tomography (SPECT) can be used in evaluating the neurodegenerative disease[9]. The effect of EGF in neurodegenerative disease is well documented in previous reports, the correlation of EGF with DAT in healthy controls has not been investigated yet. We evaluated the association between plasma EGF and the availability of DAT measured from 123I-FP-CIT SPECT in healthy controls in this study
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
